The nonprofit group often finds drugs to be overpriced. For the first potential COVID-19 drug, it says a price of up to $4,500 could be justified.
Gilead has yet to set a price for the coronavirus treatment remdesivir, but an influential drug pricing watchdog says it could be worth up to $4,500 per patient
